Q2 outcome
Sales was SEK 2,395m (+2% vs. ABG 2,345m, +2% vs. IR cons 2,351m), down 2% y-o-y, although organic growth was +4% (ABG +2%). EBITA came in at SEK 277m (+5% vs ABG 264m, +7% vs. cons 259m), for an EBITA margin of 11.6% (ABG 11.2%, cons 11.0%). The EBITA beat was mainly driven by Engineered Solutions (+14% vs. cons.), but Medical Solutions was also above (+4%). FCF was decent at SEK 128m (ABG 169m), for an FCF/net income of 60%.
LÄS MER
